Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Relmada Therapeutics
AddedFeb 20, 2024
UpdatedJun 18, 2026
Relmada Therapeutics

Relmada Therapeutics

Public

Relmada Therapeutics: A public, clinical-stage pharma company specializing in pain treatment drugs.

HQ
New York City, NY, US
Founded
2012
Overview
Compare
Fundraising
Employees
Website

Relmada Therapeutics, Inc. is a public, clinical-stage specialty pharmaceutical company founded with the mission to develop innovative treatments for pain management. The company focuses on repurposing established drug products and researching new chemical entities to address chronic pain conditions. Their primary product pipeline includes REL-1017, a novel NMDA receptor antagonist aimed at treating major depressive disorder and neuropathic pain. Relmada's market focus is on providing effective, non-opioid alternatives for pain relief, addressing a significant unmet need in the healthcare sector.

Notable figures affiliated with Relmada Therapeutics include key researchers and executives who have contributed to the company's advancements in pain treatment. The company has garnered attention from prominent investors and has participated in high-profile conferences such as the Goldman Sachs Annual Global Healthcare Conference and the Jefferies Global Healthcare Conference. Among its key achievements, Relmada has published promising results from its Phase 3 Reliance I study of REL-1017 in The Journal of Clinical Psychiatry, underscoring its potential impact on pain management and mental health treatment.

Relmada Therapeutics - Quick Facts

When was Relmada Therapeutics founded?

Relmada Therapeutics was founded in 2012.

Where is Relmada Therapeutics' headquarters located?

Relmada Therapeutics' headquarters is located in New York City, NY, US.

When was Relmada Therapeutics' last funding round?

Relmada Therapeutics' most recent funding round was for $150M (USD) in December 2021.

How much has Relmada Therapeutics raised to-date?

As of Dec 8, 2021, Relmada Therapeutics has raised a total of $191.1M (USD).

How many employees does Relmada Therapeutics have?

Relmada Therapeutics has 14 employees as of Feb 5, 2024.

Relmada Therapeutics - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pain Treatment
Tags
  • Pharma
Unique IDs
  • ein: 455401931
  • secCik: 0001553643
  • ticker: RLMD
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research